Depression and pegylated interferon-based hepatitis C treatment
Haris Papafragkakis1, Murali S Rao2, Martin Moehlen3, Sonu Dhillon4, Paul Martin1
1Division of Hepatology, University of Miami Miller School of Medicine, Miami, FL, 2Department of Psychiatry and Behavioral Neurosciences, Loyola University Medical Center, Maywood, IL, 3Division of Gastroenterology and Hepatology, Tulane University, New Orleans, LA, 4Division of Gastroenterology and Hepatology, St Francis Medical Center, Peoria, IL, USA
Abstract: Interferon remains an essential component of treatment regimens for chronic hepatitis C infection. Mood disturbances, including depression, are relatively common in the hepatitis C virus-infected population and may worsen during hepatitis C treatment. Screening for depression prior to commencement of therapy is crucial and may improve treatment outcomes. Whether prophylactic antidepressant therapy should be initiated prior to therapy of hepatitis C virus infection with an interferon-based regimen remains unclear. We review the epidemiology, diagnosis, and management of depression before and during treatment of hepatitis C virus infection with interferon.
Keywords: pegylated interferon, hepatitis C, depression, suicide risk, cytokines
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]